Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, perampanel (Fycompa®) cannot be endorsed for use within NHS Wales for the adjunctive treatment of primary generalised tonic-clonic seizures in patients from 7 years of age with idiopathic generalised epilepsy. |
||
|
||
Medicine details |
||
| Medicine name | perampanel (Fycompa®) | |
| Formulation | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablet; 0.5 mg per millilitre oral suspension | |
| Reference number | 1633 | |
| Indication | Adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age with idiopathic generalised epilepsy (IGE) |
|
| Company | Eisai Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 17/11/2015 | |
| Date of issue | 18/11/2015 | |